Citations

Clear

1417 citation(s) found for "Li, Simon".

Longitudinal behavioral and neuropsychiatric changes and their MRI correlates in predementia C9orf72 and GRN mutation carriers
Lee, Hyunwoo , Chatterjee, Atri , Mackenzie, Ian R. , Scott, Imogene, Popuri, Karteek , Wittenberg, Dana, Rademakers, Rosa , Beg, Mirza Faisal , Hsiung, Ging‐Yuek Robin

Mayo Clinic

Journal of Alzheimer’s Disease | June 19, 2025 | Volume: 106 | Issue: 3 | Pages: 928-942

10.1177/13872877251350684 | PMID 40534487 Get It

Background Neuropsychiatric symptoms (NPS) progress differently among individuals with autosomal dominant familial frontotemporal dementia (FTD) caused by genetic mutations in granulin ( GRN +) or chromosome 9 open reading frame 72 ( C9orf72 +). Objective To determine whether these differences begin prior to the onset of dementia, we compared the longitudinal rates of change of NPS among C9orf72 +, GRN +, and noncarrier controls in the predementia phase. Additionally, we assessed whether the NPS changes were correlated with gray matter (GM) volume loss or white matter signal abnormalities (WMSAs) on magnetic resonance imaging (MRI). Methods Eighty-two participants (N = 10 GRN +, N = 23 C9orf72 +, N = 49 noncarriers) were followed using various NPS rating scales for an average of 7.8 years. Group differences were compared using generalized linear mixed-effects models. GM volume and WMSA volumes were measured on 42 participants (N = 8 GRN +, N = 11 C9orf72 +, N = 23 noncarriers) who had two MRI visits. These measures were correlated with the rates of NPS score changes. Results C9orf72 + showed higher rates of increase in the Beck Depression Inventory (BDI) total and the Iowa Scales of Personality Change (ISPC) dysexecutive disturbance scores versus noncarriers. GRN + showed higher rates of increase in the BDI total, the ISPC total, and the emotional/social disturbance scores versus noncarriers; and higher rates of increase in the ISPC emotional/social personality and distressed disturbance scores versus C9orf72 +. Across all groups, faster WMSA accumulation correlated with higher rates of increase in the Neuropsychiatric Inventory Questionnaire total score. Conclusions Changes in NPS differ among C9orf72 +, GRN +, and noncarrier controls prior to the onset of overt FTD.
Transcranial Electrical Stimulation in Treatment of Depression
Ren, Caili , Wang, Zhen , Kung, Simon , Boyapati, Renu Bhargavi, Islam, Karimul , Li, John Wing , Shelton, K. Maureen, Waniger, Anne , Rydberg, Ann , Pascual–Leone, A., Pagali, Sandeep R. , Li, John W, Rydberg, Ann M, Boyapati, Renu Bhargavi, Islam, Karimul, Hassett, Leslie C. , Croarkin, Paul E. , Lundstrom, Brian N. , Lapid, Maria I.

Mayo Clinic

JAMA Network Open | June 18, 2025 | Volume: 8 | Issue: 6 | Pages: e2516459

10.1001/jamanetworkopen.2025.16459 | PMID 40531534 Get It

Importance The role and safety of transcranial electrical stimulation (tES) for treating depressive disorders remain under evaluation. Objective To evaluate tES treatment in patients with major depressive disorder (MDD) and comorbid depressive conditions. Data Sources A search of MEDLINE, Embase, Cochrane, APA PsycINFO, and Scopus databases was conducted from inception to September 17, 2024. Study Selection Randomized clinical trials (RCTs) of adults with MDD, depression with psychiatric comorbidities (DPC), or depression with medical comorbidities (DMC), treated with transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS), compared with sham or other treatments were included. Data Extraction and Synthesis Independent reviewers extracted data in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, with random-effects meta-analysis used for pooling. Main Outcomes and Measures Primary outcomes were depression severity, response and remission rates, and adverse events. Standardized mean differences (SMDs) were reported for continuous outcomes, and odds ratios (ORs) were reported for categorical outcomes. Quality of evidence (QOE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation criteria. Results The meta-analysis included 5522 participants from 114 study groups from 88 RCTs (3198 female [58.9%]; mean [range] age, 43.1 [19.4-76.9] years). Most studies (104 study groups from 79 RCTs [91.2%]) evaluated tDCS, while 7 study groups from 6 RCTs (6.1%) evaluated tACS, and 3 study groups from 3 RCTs (2.7%) evaluated tRNS. tES was associated with reduced depressive symptoms (SMD = −0.59; 95% CI, −0.83 to −0.35; low QOE) and improvement in DMC (SMD = −1.05; 95% CI, −1.67 to −0.43; low QOE) and DPC (SMD = −0.78; 95% CI, −1.27 to −0.29; low QOE) compared with MDD (SMD = −0.22; 95% CI, −0.44 to 0.01; low QOE). tDCS was associated with reduced depression in DMC (SMD = −1.05; 95% CI, −1.70 to −0.40; very low QOE) and DPC (SMD = −0.88; 95% CI, −1.40 to −0.36; low QOE) but not MDD. tACS was associated with improved MDD symptoms (SMD = −0.58; 95% CI, −0.96 to −0.20; high QOE) and response rates (OR, 2.07; 95% CI, 1.34 to 3.19; high QOE). Combined tDCS and medication was associated with reduced symptoms (SMD = −0.51; 95% CI, −0.90 to −0.13; moderate QOE) and increased response (OR, 2.25; 95% CI, 1.08 to 4.65; high QOE) in MDD. tDCS combined with psychotherapy was not associated with improvement. Subgroup analysis showed that anodal left dorsolateral prefrontal cortex DCS was associated with improved outcomes. Mild to moderate adverse events were more frequent in tES groups. Conclusions and Relevance In this systematic review and meta-analysis, tDCS was associated with improvement in depression among patients with DMC and DPC (with smaller benefits in MDD), tACS was associated with improved MDD outcomes (while tRNS had insufficient evidence) in smaller samples, and combined tDCS and medication was associated with improvement in depression. These findings suggest that tES is well-tolerated overall, with only mild to moderate adverse events, and that future research should optimize stimulation parameters and individualize tES interventions.
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Wolf, Denise M. , Yau, Christina , Glas, Annuska M. , Barcaru, Andrei, Kuilman, Midas M. , Swigart, Lamorna Brown , Hirst, Gillian L. , Basu, A. , Magbanua, Mark Jesus M. , Sayaman, Rosalyn W. , Huppert, Laura A. , Investigators, I-SPY2, Borowsky, Alexander D. , Pohlmann, Paula R. , Clark, Amy S. , Yee, Douglas , Perlmutter, Jane , Petricoin, Emanuel F. , Chien, A. Jo , Stringer-Reasor, Erica , Liu, Minetta C. , Nanda, Rita , Veer, Laura van ‘t , Melisko, Michelle , Albain, Kathy S. , Robinson, Patricia A. , Lo, Simon S. , Potter, David J. , Beckwith, Heather , Haddad, Tufia C. , Kemmer, Kathleen, Lu, Janice , Williams, Nicole , Ellis, Erin D. , Sanford, Amy, Sanft, Tara, Viscusi, Rebecca K., Arora, Mili, Northfelt, Donald W. , Haley, Barbara , Yung, Rachel L. , Mayer, Ingrid, Khan, Qamar J. , Edmiston, Kirsten K., Glas, Annuska , Mittempergher, Lorenza , Brown-Swigart, Lamorna , Hirst, Gillian L , Basu, Amrita , Magbanua, Mark J M , Sayaman, Rosalyn , Huppert, Laura , Delson, Amy , Symmans, W Fraser , Pohlmann, Paula , Rugo, Hope S , Clark, Amy S , Yee, Douglas , DeMichele, Angela , Petricoin, Emmanuel F , Chien, Jo , Stringer-Reasor, Erica , Shatsky, Rebecca , Liu, Minetta , Soliman, Hatem Hussein , Isaacs, Claudine , Nanda, Rita , Hylton, Nola M. , Pusztai, Lajos , Esserman, Laura J , Veer, Laura J. van’t , Campbell, Michael, Investigators, I-SPY2, Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Shatsky, Rebecca , Han, Hyo S , Isaacs, Claudine , Pusztai, Lajos , Esserman, Laura J. , Mukhtar, Rita A. , Wallace, Anne M. , Yeung, Kay T. , Olopade, Olufunmilayo I. , Potter, David, Blaes, Anne , Boughey, Judy C. , Elias, Anthony , Mitri, Zahi Ibrahim , Lang, Julie E. , Thomas, Alexandra , Trivedi, Meghna S. , Hershman, Dawn L. , Meisel, Jane Lowe , Kalinsky, Kevin M. , Vaklavas, Christos , Sanft, Tara , Arora, Mili, Falkson, Carla I. , Murthy, Rashmi Krishna

Mayo Clinic

JCO Precision Oncology | June 17, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00776 | PMID 40526879 Get It

PURPOSE Neoadjuvant immunotherapy (IO) has become the standard of care for early-stage triple-negative breast cancer (TNBC), but not yet for other subtypes. We previously developed a clinical-grade mRNA-based immune classifier (ImPrint) predicting response to IO that is now being used in I-SPY2.2 as part of the response predictive subtypes. We report the performance of ImPrint in hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+HER2–) patients from five IO arms. METHODS A total of 204 HR+HER2– (MammaPrint high-risk) patients from five IO arms (anti–PD-1, anti–PD-L1/poly [ADP-ribose] polymerase inhibitor combination, anti–PD-1/toll-like receptor 9 dual-IO combination, and anti–PD-1 ± lymphocyte activation gene 3 dual-IO combination) and 191 patients from the chemotherapy-only control arm were included in this analysis. Patients were classified as ImPrint+ (likely sensitive) versus ImPrint– (likely resistant), using pretreatment mRNA. Performance of ImPrint for predicting pathologic complete response (pCR) to IO-containing arms was characterized and compared with tumor grade (III), MammaPrint (ultra) High2 risk (MP2), and estrogen receptor (ER)-low (ER ≤ 10%). RESULTS Overall, the pCR rate across the five IO arms was 33%. 26% of HR+HER2– patients were ImPrint+, and pCR rates with IO were 75% in ImPrint+ versus 17% in ImPrint–, with the highest pCR rate >90% in a dual-IO arm. In the control arm, pCR rates were 33% in ImPrint+ and 8% in ImPrint–. Tumor grade (III), MP2, and ER-low showed pCR rates in IO of 45%, 56%, and 63%, respectively, with lower pCR odds ratios (OR < 7.5) compared with ImPrint (OR = 14.5). CONCLUSION Using an accurate selection strategy, HR+HER2– patients could achieve pCR rates similar to what is seen with best neoadjuvant therapies in TNBC and HER2+ (ie, pCR rate >65%-70%). ImPrint, an Food and Drug Administration IDE-enabled assay, may represent a way to identify HR+HER2– patients for IO that best balances likely benefit versus risk of serious immune-related adverse events.
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Raghavan, Sheelakumari, Costoya‐Sánchez, Alejandro , Mainta, Ismini , Rodríguez-Fonseca, Omar Darío, Perissinotti, Andrés , Gu, Yuna , Yun, Jihwan, Peretti, Débora Elisa , Aguiar, Pablo , Bischof, Gérard N. , Seo, Sang Won , Villeneuve, Sylvia , O’Brien, John T. , Jagust, William, Frisoni, Giovanni B. , Soleimani‐Meigooni, David N. , Carrillo, Marı́a C., Joie, Renaud La , Rabinovici, Gil D. , Apostolova, Liana G. , Pontecorvo, Michael J. , Johnson, Keith A. , Weiner, Michael W. , Petersen, Ronald C., Jack, Clifford R. , Schöll, Michael , Labonté, Anne , Faubert, Anne‐Marie, Mathieu, Axel, Madjar, Cécile , Carrier, Charles Edouard, Kazazian, Christina, Lepage, Claude, Maillet, David , Michaud, Diane, Couture, Doris, Dea, Doris, Courcot, Blandine, Debacker, Clément , Fontaine, David, Knopman, David S. , Multhaup, Gerhard, Maltais, Jean‐Robert, Breitner, John C.S. , Poirier, Judes, Cheewakriengkrai, Laksanun, Sager, Mark A., Dauar‐Tedeschi, Marina, Rajah, Natasha, Aisen, Paul, Toussaint, Paule‐Joanne , Pierre, Bellec, Kostopoulos, Penelope, Étienne, Pierre , Tariot, Pierre N. , Orban, Pierre , Hoge, Rick, Thomas, Ronald J. , Gauthier, Serge , Craft, Suzanne , Montine, Thomas J. , Nair, Vasavan, Bohbot, Véronique D. , Venugopalan, Vinod, Ituria‐Medina, Yasser, Khachaturian, Zaven S., Teigner, Eduard, Anthal, Elena, Yu, Elsa, Ferdinand, Fabiola, Pogossova, Galina, Mayrand, Ginette, Duclair, Guerda, Gagné, Guylaine, Newbold‐Fox, Holly, Leppert, Illana, Tremblay‐Mercier, Jennifer , Frenette, Joanne, Frappier, Josée, Kat, Justin, Miron, Justin , Wan, Karen, Mahar, Laura, Carmo, Leopoldina, Théroux, Louise, Dufour, Marianne, Lafaille‐Magnan, Marie‐Élyse, Savard, Mélissa, Tuwaig, Miranda, Petkova, Mirela, Rioux, Pierre, Meyer, P.T., El‐Khoury, Rana, Gordon, Renee, Giles, Renuka, Das, Samir, Wang, Seqian, Tabrizi, Shirin , Mathotaarachchi, Sulantha , Dubuc, Sylvie, Lee, Tanya , Beaudry, Thomas, Gervais, Valérie, Pagé, Véronique, Desautels, René, Benbouhoud, Fatiha, Saint‐Fort, Eunice Farah, Verfaillie, Sander C.J. , Farzin, Sarah , Salaciak, Alyssa , Tullo, Stéphanie , Daoust, Leslie‐Ann, Köbe, Theresa , McSweeney, Melissa, Nilsson, Nathalie , Pishnamazi, Morteza, Bedetti, Christophe , Hudon, Louise, Greco, Claudia, Chapleau, Marianne , St‐Onge, Frédéric , Boutin, Sophie , Geddes, Maiya R. , Ducharme, Simon , Jean, Gabriel, Sylvain, Elisabeth, Élie, Marie‐Josee, Leblond‐Baccichet, Gloria, Soucy, Jean‐Paul , Ozlen, Hazal , Bailly, Julie, Mohammediyan, Béry, Chen, Yalin , Remz, Jordana, Rentz, Dorene M., Amariglio, Rebecca E. , Blacker, Deborah , Chhatwal, Jasmeer P. , Dickerson, Brad C., Donovan, Nancy J. , Farrell, Michelle E. , Gómez, Cristina Lois, Marshall, Gad A. , Oaoo, Kate, Price, Julie, Prokopiou, Prokopis C. , Reynolds, Gretchen , Skylar-Scott, Irina A., Vila‐Castelar, Clara , Yang, Hyun‐Sik , Trojanowki, John Q., Green, Robert C, Perrin, Richard J. , Shaw, Leslie M. , Potter, William Z. , Bernard, Marie , Jackson, Jonathan, Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma, Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Mariam, Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Rafii, Michael, Raman, Rema , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Smith, Stephanie , Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Harvey, Danielle, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Kantarci, Kejal, Thompson, Paul , Jahanshad, Neda , DeCarli, Charles , Knaack, Alexander , Fletcher, Evan, Chen, Stephanie R, Choe, Mark, Crawford, Karen , Yuschkevich, Paul A, Reiman, Eric M. , Mathis, Chet, Landau, Susan , Cairns, Nigel J. , Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michal, Neu, Scott, Nho, Kwangsik, Foroud, Tatiana M., Faber, Kelley , Wilmes, Kristi, Thal, Leon J., Dage, Jeffrey L. , Eloyan, Ani , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel, Legarde, Julien, Murray, Melissa E., Newell, Kathy L. , Taurone, Alexander, Thangarajah, Maryanne, Touroutoglou, Alexandra , Clark, David , Day, Gregory S, Duara, Ranjan , Graff-Radford, Neill R, Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Carrillo, María C. , O'Brien, John Tiernan , Jack, Clifford R , Schöll, Michael , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Rial, Alexis Moscoso , Heeman, Fiona , Raghavan, Sheelakumari , Essen, Martijn van , Camacho, Valle , Silva‐Rodríguez, Jesús , Ribaldi, Federica , Coomans, Emma M. , Brum, Wagner Scheeren , Grothe, Michel J. , Drzezga, Alexander E. , Malpetti, Maura , Rowe, James B. , Giessen, Elsmarieke van de , Ossenkoppele, Rik , Smith, Ruben , Hansson, Oskar , Garibotto, Valentina , Dickerson, Bradford Clark , LaMontagne, Pamela , Sperling, Reisa Anne , Vemuri, Prashanthi , Tam, Angela , Binette, Alexa Pichet , Dansereau, Christian , Picard, Cynthia , Michaud, Diane, Couture, Doris, Cuello, A. Claudio , Barkun, Alan , Evans, Alan Charles , Tardif, Christine Lucas , Knopman, David S. , Near, Jamie , Leoutsakos, Jeannie‐Marie , Brandt, Jason , Pruessner, Jens C. , Morris, John C. , Collins, D. Louis , Chakravarty, M. Mallar , Eisenberg, Mark Jeffrey , Rajah, Maria Natasha , Rosa-Neto, Pedro , Bellec, Pierre , Thomas, Ronald, Fonov, Vladimir , Vallee, Isabelle, Vogel, Jacob W. , Dadar, Mahsa , Appleby, Melissa , Meyer, Pierre‐François, Gonneaud, Julie , Pascoal, Tharick Ali , Vachon‐Presseau, Étienne , Spreng, R. Nathan , Rentz, Dorene M. , Buckley, Rachel F. , Gagliardi, Geoffroy Pierre , Gatchel, Jennifer R. , Guzmán‐Vélez, Edmarie , Jacobs, Heidi I.L. , Jutten, Roos J. , Pardilla‐Delgado, Enmanuelle , Price, Julie C. , Quiroz, Yakeel T. , Schultz, Aaron P. , Schultz, Stephanie A. , Sepulcre, Jorge , Vannini, Patrizia , Toga, Arthur W. , Beckett, Laurel , Saykin, Andrew J. , Potter, William, Barnes, Lisa L. , Gonzalez, Hector, Ho, Carole , Hsiao, John , Jackson, Jonathan , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Jimenez‐Maggiora, Gustavo Adolfo , Donohue, Michael , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Kantarci, Kejal , Senjem, Matthew L. , Reid, Robert I. , Fox, Nick C. , Malone, Ian B. , Thomopoulos, Sophia I. , Nir, Talia M. , Tosun, Duygu , Das, Sandhitsu R. , Koeppe, Robert A. , Chen, Kewei , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Ghetti, Bernardino , Grinberg, Lea T. , Hammers, Dustin B , Kirby, Kala, Kukull, Walter A. , Murray, Melissa E. , Polsinelli, Angelina J. , Atri, Alireza , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Musiek, Erik , Salloway, Steve , Turner, Raymond Scott , Wingo, Thomas S , Wolk, S. J. , Womack, Kyle

Mayo Clinic

JAMA | June 16, 2025 | Volume: 334 | Issue: 3 | Pages: 229

10.1001/jama.2025.7817 | PMID 40522652 Get It

Importance Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD). Objective To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes. Design, Setting, and Participants Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included. Exposures Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration– and European Medicines Agency–approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI). Main Outcomes and Measures Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia). Results Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET–positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET–positive/tau PET–negative (17% [95% CI, 13%-22%]) and Aβ PET–negative/tau PET–negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET–positive/tau PET–positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%). Conclusions and Relevance In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.
MKK4 and MKK7 control degeneration of retinal ganglion cell somas and axons after glaucoma-relevant injury.
Yablonski, S. , Shrager, Peter, John, Simon W. M. , Libby, Richard T. , Marola, Olivia J. , Syc‐Mazurek, Stephanie B.

Mayo Clinic

No container title available | June 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6805128/v1 Get It

Abstract Glaucoma is characterized by programmed cell death of retinal ganglion cells (RGCs) after axonal injury. Several studies have shown the cell-intrinsic drivers of RGC degeneration act in a compartment-specific manor. Recently, the transcription factors JUN and DDIT3 were identified as critical hubs regulating RGC somal loss after mechanical axonal injury. It is possible somal DDIT3 and JUN activity initiates axonal degeneration mechanisms in glaucoma. Alternatively, DDIT3 and JUN may act downstream of inciting degenerative mechanisms and only drive RGC somal loss. The MAP2Ks MKK4 and MKK7 control all JNK and JUN activity and can indirectly activate DDIT3. Furthermore, MKK4 and MKK7 have been shown to drive RGC axonal degeneration after mechanical axonal injury. The present work investigated whether JUN and DDIT3, or their upstream activators MKK4 and MKK7, control degeneration of RGC axons and somas after glaucoma-relevant injury. Ddit3 and Jun deletion did not prevent axonal degeneration in ocular hypertensive DBA/2J mice but prevented nearly all RGC somal loss. Despite robust somal survival, Ddit3 and Jun deletion did not preserve RGC somal viability (as assessed by PERG decline and soma shrinkage) in DBA/2J mice or after glaucoma-relevant mechanical axonal injury. In contrast, Mkk4 and Mkk7 deletion significantly lessened degeneration of RGC somas and axons, and preserved somal function and size after axonal injury. In summary, activation of MKK4 and MKK7 appears to be the inciting mechanism governing death of the entire RGC after glaucoma-relevant injury; driving death of the RGC soma (likely through activation of DDIT3 and JUN), decline in somal viability, and axonal degeneration via DDIT3 and JUN-independent mechanisms.
NCCN Guidelines® Insights: Survivorship, Version 2.2025
Sanft, Tara , Ansbaugh, Shannon M., Ariza‐Heredia, Ella , Ballinger, Tarah J. , Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Hill‐Kayser, Christine E. , Hock, Karen , Kline‐Quiroz, Cristina , Koura, Divya, McDonough, Allison L. , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Saidain, Ava, Schapira, Lidia , Tenne, Laura, Ah, Diane Von , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Ballinger, Tarah Jean , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Cathcart-Rake, Elizabeth , Evgeniou, Evgenios , Friedman, Debra L. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Rogers, Laura Q. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 208-217

10.6004/jnccn.2025.0028 | PMID 40499584 Get It

The NCCN Guidelines for Survivorship include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from adult-onset cancer and its treatment and provide a framework for coordination of survivorship care. They also include recommendations to help cancer survivors enhance their wellness and maintain a healthy lifestyle. These NCCN Guidelines Insights summarize the panel’s current recommendations and recent updates regarding physical activity, nutrition, and weight management for cancer survivors.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Avet‐Loiseau, Hervé , Davies, Faith E. , Samur, Mehmet , Corre, Jill , D’Agostino, Mattia , Kaiser, Martin , Raab, Marc S. , Weinhold, Niels , Gutiérrez, Norma C. , Paiva, Bruno , Walker, Brian A. , Bustoros, Mark , Stewart, A. Keith , Hillengaß, Jens , Martínez‐López, Joaquín , Sperling, Adam S. , Dhodapkar, Madhav V. , Spencer, Andrew , Parekh, Samir , Sonneveld, Pieter , Bergsagel, P. Leif , Orlowski, Robert Z. , Mateos, María‐Victoria , Kumar, Shaji , Munshi, Nikhil C. , Martinez-Lopez, Joaquin , Bergsagel, P. Leif , Samur, Mehmet K , Kaiser, Martin F , Weisel, Katja C , Maura, Francesco , Walker, Brian A , Bustoros, Mark , Stewart, A Keith , Usmani, Saad , Hillengass, Jens , Chng, Wee Joo , Keats, Jonathan J , Martinez-Lopez, Joaquin , Sperling, Adam S , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur S , Bolli, Niccolo' , Ghobrial, Irene M , Dhodapkar, Madhav V , Jagannath, Sundar , Spencer, Andrew , Parekh, Samir , Bahlis, Nizar Jacques , Sonneveld, Pieter , Orlowski, Robert Z. , Mateos, María-Victoria , San-Miguel, Jesus , Anderson, Kenneth C , Moreau, Philippe , Kumar, Shaji K , Munshi, Nikhil C , Raab, Marc S , Martinez-Lopez, Joaquin , Paiva, Bruno , Davies, Faith E , Corre, Jill , Mattia, D'Agostino , Neri, Paola , Maura, Francesco , Usmani, Saad Z. , Chng, Wee Joo , Keats, Jonathan J. , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur , Cavo, Michèle , Bolli, Niccolò , Ghobrial, Irene M. , Jagannath, Sundar , Lonial, Sagar , Morgan, Gareth J. , Rajkumar, S. Vincent , Miguel, Jesús F. San , Anderson, Kenneth C. , Moreau, Philippe , Prósper, Felipe

Mayo Clinic

Journal of Clinical Oncology | June 9, 2025 | Volume: 43 | Issue: 24 | Pages: 2739-2751

10.1200/jco-24-01893 | PMID 40489728 Get It

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
CD39 REGULATES P2RX7-MEDIATED LUNG NECROTIC LESIONS IN SEVERE EXPERIMENTAL TUBERCULOSIS
Santos, Gislane de Almeida , Santiago-Carvalho, Igor , Almeida, Fabrício Moreira, Bomfim, Caio César Barbosa , Silva, Juan Carlo Santos e , Cantarini, D. , Silva, Camila Ramos , Raeder, Paulo Henrique Lisboa, Teixeira-Xavier, Joaquim , Álvarez, José María , de Almeida Santos, Gislane , Ribeiro, Martha Simões , Nascimento, Rogério Silva do , Macedo, Bruna de Gois , Raeder, Paulo Lisboa , Hirata, Mário Hiroyuki , Coutinho‐Silva, Robson , Robson, Simon Christopher , Amaral, Eduardo P. , Lasunskaia, Elena , Lima, Maria Regina D’Império

Mayo Clinic

No container title available | May 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.28.656614 Get It

SUMMARY Tuberculosis induces diverse lesions, such as necrotic pneumonia, contributing to disease progression and transmission. Despite advances in understanding the role of ATP-gated P2RX7 ion channels in developing severe forms of tuberculosis, the regulation of this important signaling pathway remains unclear. Herein, we show that the ectonucleotidase CD39 plays an essential regulatory role in TB progression by preventing lung tissue damage, bacterial dissemination, and excessive inflammatory responses. Mechanistically, through its enzymatic activity on the cellular surface, CD39 protects infected macrophages from undergoing necrotic death mediated by P2RX7 activation. We proposed that by protecting macrophages from P2RX7-mediated cell death and bacterial dissemination, CD39 prevents the development of necrotic lesions. Altogether, these findings uncover a significant role for CD39 as an essential component of the molecular regulation underlying the development of severe tuberculosis. GRAPHICAL ABSTRACT Brief In tuberculosis, necrotic granuloma-like structures release extracellular ATP (eATP), which triggers P2RX7-mediated immune cell death. CD39 degrades eATP, preventing P2RX7 activation and promoting macrophage survival, thereby limiting inflammation, tissue damage, and bacterial dissemination.